Dravet Syndrome: A Rare Epilepsy, Now With Two Approved Treatments

Dravet syndrome begins in early childhood, but following FDA approval of Diacomit (stiripentol) from Biocodex two drugs have been cleared this year to treat the disease in the US and, with multiple other treatment options in the pipeline, one more could be approved in 2019.

Gentilly, France-based Biocodex announced on Aug. 23 that FDA approved Diacomit for seizures associated with Dravet syndrome in patients aged 2 and older when already being treated with clobazam. The agency's Aug